PT - JOURNAL ARTICLE AU - Zehua Wang AU - Haiou Liu AU - Congjian Xu TI - Cellular Senescence in the Treatment of Ovarian Cancer AID - 10.1097/IGC.0000000000001257 DP - 2018 Jun 01 TA - International Journal of Gynecologic Cancer PG - 895--902 VI - 28 IP - 5 4099 - http://ijgc.bmj.com/content/28/5/895.short 4100 - http://ijgc.bmj.com/content/28/5/895.full SO - Int J Gynecol Cancer2018 Jun 01; 28 AB - Objective This review aimed to update the research and development of cellular senescence in the treatment of ovarian cancer. We discussed the current mechanisms of senescence and the major biomarkers of senescence, especially the methods of cellular senescence in the treatment of ovarian cancer.Materials and Methods We collected all relevant studies in PubMed from 1995 to 2017. The search terms included senescence and cancer, senescence and ovarian cancer, senescence-associated secretory phenotype, ovarian cancer and chemotherapy, radiotherapy, or biotherapy. PubMed search with the key words senescence and ovarian cancer lists approximately 85 publications. After excluding the duplicated articles, we selected 68 articles most relevant to senescence and ovarian cancer in this review.Results Cellular senescence plays a key role in various biological processes of ovarian cancer, which is closely related with the occurrence, development, and treatment of ovarian cancer. Cellular senescence on the one hand can reduce the dose of chemotherapy in ovarian cancer; on the other hand, it also can solve the problem of tumor resistance to apoptosis. Therefore, cellular senescence has been shown to be the third intracellular mechanism of ovarian cancer prevention followed by cellular DNA repair and apoptosis.Conclusions In the near future, cellular senescence therapy could be a powerful tool for ovarian cancer treatment.